Physician profile
Jonathan G Evans
NPI 1568460640
$321,512.60
in general payments reported to CMS, 2019-2025
48 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $43K · 2021: $54K · 2022: $62K · 2023: $78K · 2024: $24K · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Travel and Lodging: $6,748 · Food and Beverage: $5,052 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,261.52 |
| Travel and Lodging | $6,748.10 |
| Food and Beverage | $5,051.63 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $151,387.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $60,350.61 | 2019-2024 | Breztri, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $25,223.37 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $20,429.24 | 2019-2025 | |
| Mylan Specialty L.P. | $17,026.46 | 2019-2024 | Yupelri, Yupelri |
| Idorsia Pharmaceuticals US INC | $16,249.31 | 2022-2024 | Quviviq |
| Harmony Biosciences LLC | $10,560.84 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $10,313.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,083.39 | 2019-2022 | |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $1,542.45 | 2019-2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $755.18 | 2019-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Insmed, INC. | $690.42 | 2019-2023 | |
| Genzyme Corporation | $531.04 | 2019-2025 | |
| Olympus Corporation of The Americas | $370.60 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.